Toceranib

Base Information

• Chemical Name: Toceranib
• CAS No.: 356068-94-5
• Molecular Formula: C22H25FN4O2
• Molecular Weight: 396.46
• UNII: 59L7Y0530C
• DSSTox Substance ID: DTXSID50189076
• Nikkaji Number: J3.311.001D
• Wikipedia: Toceranib
• Wikidata: Q76304061
• NCI Thesaurus Code: C80870
• RXCUI: 1145945
• Pharos Ligand ID: 82LP8VJL7M48
• ChEMBL ID: CHEMBL13608
• Mol file: 356068-94-5.mol

Synonyms:palladia;SU 11654;SU-11654;SU11654;toceranib phosphate

Chemical Property of Toceranib

Chemical Property:

• Boiling Point: 596.8±50.0 °C(Predicted)
• PKA: 11.70±0.20(Predicted)
• PSA: 77.23000
• Density: 1.293
• LogP: 3.55570
• Storage Temp.: room temp
• Solubility.: DMSO (Slightly, Heated), Methanol (Very Slightly, Heated)
• XLogP3: 2.4
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 5
• Exact Mass: 396.19615422
• Heavy Atom Count: 29
• Complexity: 663

Purity/Quality:

98%,99%, ^*data from raw suppliers

Toceranib ≥98%(HPLC) ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)C=C3C4=C(C=CC(=C4)F)NC3=O
• Isomeric SMILES: CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O
• Uses: Toceranib is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor. Toceranib exhibited activity against a variety of spontaneous malignancies in canine such as mast cell tumors, mixed m ammary carcinomas, soft tissue sarcomas, and multiple myeloma. Labelled Toceranib, a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor. Toceranib exhibited activity against a variety of spontaneous malignancies in canine such as mast cell tumors, mixed mammary carcinomas, soft tissue sarcomas, and multiple myeloma. Toceranib is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor. Toceranib exhibited activity against a variety of spontaneous malignancies in canine such as mast cell tumors, mixed mammary carcinomas, soft tissue sarcomas, and multiple myeloma.